ZA200107450B - Dimeric compounds and their use as inhibitors of neuraminidase. - Google Patents
Dimeric compounds and their use as inhibitors of neuraminidase.Info
- Publication number
- ZA200107450B ZA200107450B ZA200107450A ZA200107450A ZA200107450B ZA 200107450 B ZA200107450 B ZA 200107450B ZA 200107450 A ZA200107450 A ZA 200107450A ZA 200107450 A ZA200107450 A ZA 200107450A ZA 200107450 B ZA200107450 B ZA 200107450B
- Authority
- ZA
- South Africa
- Prior art keywords
- neuraminidase
- inhibitors
- dimeric compounds
- dimeric
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP9139A AUPP913999A0 (en) | 1999-03-12 | 1999-03-12 | Novel chemical compounds and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200107450B true ZA200107450B (en) | 2002-09-10 |
Family
ID=3813338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200107450A ZA200107450B (en) | 1999-03-12 | 2001-09-10 | Dimeric compounds and their use as inhibitors of neuraminidase. |
Country Status (26)
Country | Link |
---|---|
US (1) | US6548476B1 (de) |
EP (1) | EP1165541B1 (de) |
JP (1) | JP5160000B2 (de) |
KR (1) | KR100805906B1 (de) |
CN (1) | CN1343205A (de) |
AP (1) | AP2001002277A0 (de) |
AT (1) | ATE295361T1 (de) |
AU (2) | AUPP913999A0 (de) |
BR (1) | BR0008939A (de) |
CA (1) | CA2367755C (de) |
CZ (1) | CZ20013274A3 (de) |
DE (1) | DE60020100T2 (de) |
EA (1) | EA200100968A1 (de) |
ES (1) | ES2241581T3 (de) |
HK (1) | HK1041693B (de) |
HU (1) | HUP0200190A3 (de) |
ID (1) | ID29868A (de) |
IL (1) | IL145346A (de) |
MX (1) | MXPA01009203A (de) |
NO (1) | NO327812B1 (de) |
NZ (1) | NZ514041A (de) |
PL (1) | PL350228A1 (de) |
TR (1) | TR200102794T2 (de) |
TW (1) | TWI268279B (de) |
WO (1) | WO2000055149A1 (de) |
ZA (1) | ZA200107450B (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2271249C (en) * | 1996-11-14 | 2010-07-20 | Biota Scientific Management Pty. Ltd. | Macromolecular neuraminidase-binding compounds |
DE19930177B4 (de) * | 1999-06-30 | 2007-02-08 | Nikolai Vladimirovich Bovin | Intermolekular assoziierende Verbindungen und deren Verwendung |
AUPQ288499A0 (en) | 1999-09-16 | 1999-10-07 | Biota Scientific Management Pty Ltd | Antiviral agents |
AUPR001000A0 (en) * | 2000-09-08 | 2000-10-05 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
ES2305300T3 (es) | 2001-11-09 | 2008-11-01 | Biota Scientific Management Pty. Ltd. | Compuestos dimericos y su utilizacion como agentes antiviricos. |
AUPR879401A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
AU2002340632B2 (en) * | 2001-11-09 | 2008-03-20 | Biota Scientific Management Pty Ltd | Dimeric compounds and their use as anti-viral agents |
AU2002336823B2 (en) * | 2001-11-09 | 2008-03-20 | Biota Scientific Management Pty Ltd | Dimeric compounds and their use as anti-viral agents |
AUPR879701A0 (en) | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
AUPR879601A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
AU2002340635B2 (en) * | 2001-11-09 | 2008-03-13 | Biota Scientific Management Pty Ltd | Dimeric compounds and their use as anti-viral agents |
AUPR879501A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
MXPA05002444A (es) * | 2002-09-06 | 2005-09-30 | Insert Therapeutics Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
US7220300B2 (en) | 2004-12-04 | 2007-05-22 | Xerox Corporation | Phase change inks containing bis(urea-urethane) compounds |
US7317122B2 (en) | 2004-12-04 | 2008-01-08 | Xerox Corporation | Curable trans-1,2-cyclohexane bis(urea-urethane) compounds |
US7560587B2 (en) | 2004-12-04 | 2009-07-14 | Xerox Corporation | Bis[urea-urethane] compounds |
US7314949B2 (en) | 2004-12-04 | 2008-01-01 | Xerox Corporation | Trans-1,2-cyclohexane bis(urea-urethane) compounds |
US7144450B2 (en) * | 2004-12-04 | 2006-12-05 | Xerox Corporation | Phase change inks containing trans-1,2-cyclohexane bis(urea-urethane) compounds |
US7576235B2 (en) | 2004-12-04 | 2009-08-18 | Xerox Corporation | Processes for preparing bis(urea-urethane) compounds |
US7153349B2 (en) | 2004-12-04 | 2006-12-26 | Xerox Corporation | Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds |
AU2008208865B2 (en) * | 2007-01-23 | 2013-01-24 | Therapicon Srl | Antiviral compounds |
US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
AU2008272785B2 (en) * | 2007-07-03 | 2014-06-12 | Children's Hospital & Research Center At Oakland | Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting |
JP5597130B2 (ja) * | 2007-07-03 | 2014-10-01 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | ポリシアル酸脱n−アセチラーゼの阻害剤及びその使用方法 |
CA2690440A1 (en) | 2007-07-03 | 2009-01-08 | Children's Hospital & Research Center At Oakland | Oligosialic acid derivatives, methods of manufacture, and immunological uses |
ES2442024T3 (es) | 2008-07-15 | 2014-02-07 | Academia Sinica | Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados |
AU2010295646B2 (en) * | 2009-09-15 | 2016-02-11 | Ellipses Pharma Limited | Treatment of cancer |
IT1396620B1 (it) * | 2009-11-25 | 2012-12-14 | Therapicon Srl | Analoghi chimerici |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CN103154012B (zh) * | 2010-08-24 | 2015-11-25 | 英皇创新有限公司 | 聚丙基醚亚胺的糖树状聚体 |
CN104080450A (zh) * | 2012-01-05 | 2014-10-01 | 阿拉维制药公司 | 扎那米韦生物利用度增强的制剂 |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
JP6486368B2 (ja) | 2013-09-06 | 2019-03-20 | アカデミア シニカAcademia Sinica | 改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化 |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US9982041B2 (en) | 2014-01-16 | 2018-05-29 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3129767B1 (de) | 2014-03-27 | 2021-09-01 | Academia Sinica | Reaktive markierungsverbindungen und ihre verwendungen |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
CA2950423A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
CN106661099A (zh) | 2014-05-27 | 2017-05-10 | 中央研究院 | 抗her2醣抗体及其用途 |
KR20240096599A (ko) | 2014-05-27 | 2024-06-26 | 아카데미아 시니카 | 항-cd20 글리코항체 및 이의 용도 |
WO2015184001A1 (en) | 2014-05-28 | 2015-12-03 | Academia Sinica | Anti-tnf-alpha glycoantibodies and uses thereof |
KR102422375B1 (ko) | 2014-09-08 | 2022-07-18 | 아카데미아 시니카 | 당지질을 사용한 인간 iNKT 세포 활성화 |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
MX2018005999A (es) * | 2015-11-20 | 2018-11-22 | Australian Biomedical Co Pty Ltd | Compuestos para aplicaciones medicinales. |
RU2612221C1 (ru) * | 2015-12-16 | 2017-03-03 | Общество с ограниченной ответственностью "Синтавр" | Блокаторы вируса гриппа |
JP2019515876A (ja) | 2016-03-08 | 2019-06-13 | アカデミア シニカAcademia Sinica | N−グリカンおよびそのアレイのモジュール合成のための方法 |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
CN108003065B (zh) * | 2016-10-27 | 2021-01-08 | 中国石油化工股份有限公司 | 一种具有增稠作用的化合物和润滑脂以及它们的制备方法 |
WO2018199798A1 (ru) * | 2017-04-28 | 2018-11-01 | Общество с ограниченной ответственностью "Синтавр" | Пептидные производные противовирусного препарата занамивира |
WO2018213933A1 (en) * | 2017-05-25 | 2018-11-29 | The Governors Of The University Of Alberta | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase |
CN111698999A (zh) * | 2017-12-06 | 2020-09-22 | 阿道恰公司 | 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph为7的可注射溶液 |
EP3846846A4 (de) | 2018-09-06 | 2022-08-03 | Cidara Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von virusinfektionen |
SG11202102661UA (en) * | 2018-10-05 | 2021-04-29 | Univ Emory | Monomer and multimeric anti-hbv agents |
TW202122117A (zh) | 2019-09-06 | 2021-06-16 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2050484A1 (en) * | 1990-02-27 | 1991-08-28 | Satoru Nakabayashi | Sialic acid-containing glycolipid derivatives |
JP3476455B2 (ja) * | 1991-03-18 | 2003-12-10 | ザ スクリップス リサーチ インスティテュート | NeuAcα2、6Galβ1、4GlcNAc及びシアリルLexの合成法 |
EP0638085A1 (de) * | 1992-02-19 | 1995-02-15 | The Biomembrane Institute | Inhibition der zelladhäsion durch chemisch definierte oligosaccharide, ihre derivate, mimetika, und antikörper spezifisch dafür |
JPH0638784A (ja) * | 1992-03-30 | 1994-02-15 | Meiji Milk Prod Co Ltd | シアル酸を構成要素とする糖鎖の製造方法 |
ZA937034B (en) * | 1992-09-24 | 1995-06-23 | Brigham & Womens Hospital | Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines |
US5837689A (en) * | 1993-06-16 | 1998-11-17 | Glycomed Incorporated | Sialyl lewis-x mimetics containing naphthyl backbones |
US5658880A (en) * | 1993-06-16 | 1997-08-19 | Glycomed Incorporated | Sialic acid/fucose based medicaments |
WO1996026933A1 (en) * | 1995-02-27 | 1996-09-06 | Gilead Sciences, Inc. | Novel selective inhibitors of viral or bacterial neuraminidases |
US5780606A (en) * | 1995-06-07 | 1998-07-14 | Connaught Laboratories Limited | Neisseria meningitidis capsular polysaccharide conjugates |
DE69721242T2 (de) | 1996-03-01 | 2004-01-29 | Biota Scient Management | Verfahren zum nachweis von influenza-virus und dazu verwendbare verbindungen |
US5891862A (en) * | 1996-03-15 | 1999-04-06 | Geltex Pharmaceuticals, Inc. | Polyvalent polymers for the treatment of rotavirus infection |
AUPO104396A0 (en) | 1996-07-17 | 1996-08-08 | Biomolecular Research Institute Limited | Antiviral linear polymers |
DE69739750D1 (de) * | 1996-07-23 | 2010-03-18 | Seikagaku Kogyo Co Ltd | Neue laktosamin-oligosaccharide und verfahren zu ihrer herstellung |
CA2271249C (en) | 1996-11-14 | 2010-07-20 | Biota Scientific Management Pty. Ltd. | Macromolecular neuraminidase-binding compounds |
JPH10182686A (ja) * | 1996-12-26 | 1998-07-07 | Ngk Insulators Ltd | ガングリオシドGQ1b類縁物質 |
US6267242B1 (en) | 1997-04-17 | 2001-07-31 | Johnson & Johnson Medical Kabushiki Kaisha | Chemical indicator sheets and packaging bags for sterilization made with the use of the same |
CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
-
1999
- 1999-03-12 AU AUPP9139A patent/AUPP913999A0/en not_active Abandoned
-
2000
- 2000-03-09 ID IDW00200101979A patent/ID29868A/id unknown
- 2000-03-09 PL PL00350228A patent/PL350228A1/xx unknown
- 2000-03-09 IL IL14534600A patent/IL145346A/xx not_active IP Right Cessation
- 2000-03-09 AP APAP/P/2001/002277A patent/AP2001002277A0/en unknown
- 2000-03-09 AT AT00907354T patent/ATE295361T1/de not_active IP Right Cessation
- 2000-03-09 KR KR1020017011546A patent/KR100805906B1/ko not_active IP Right Cessation
- 2000-03-09 MX MXPA01009203A patent/MXPA01009203A/es active IP Right Grant
- 2000-03-09 CA CA002367755A patent/CA2367755C/en not_active Expired - Fee Related
- 2000-03-09 NZ NZ514041A patent/NZ514041A/xx not_active Application Discontinuation
- 2000-03-09 TR TR2001/02794T patent/TR200102794T2/xx unknown
- 2000-03-09 AU AU28966/00A patent/AU774222B2/en not_active Ceased
- 2000-03-09 JP JP2000605578A patent/JP5160000B2/ja not_active Expired - Fee Related
- 2000-03-09 EA EA200100968A patent/EA200100968A1/ru unknown
- 2000-03-09 ES ES00907354T patent/ES2241581T3/es not_active Expired - Lifetime
- 2000-03-09 CZ CZ20013274A patent/CZ20013274A3/cs unknown
- 2000-03-09 EP EP00907354A patent/EP1165541B1/de not_active Expired - Lifetime
- 2000-03-09 DE DE60020100T patent/DE60020100T2/de not_active Expired - Lifetime
- 2000-03-09 HU HU0200190A patent/HUP0200190A3/hu unknown
- 2000-03-09 WO PCT/AU2000/000165 patent/WO2000055149A1/en active IP Right Grant
- 2000-03-09 CN CN00804901A patent/CN1343205A/zh active Pending
- 2000-03-09 BR BR0008939-7A patent/BR0008939A/pt not_active IP Right Cessation
- 2000-09-08 US US09/658,445 patent/US6548476B1/en not_active Expired - Lifetime
- 2000-09-08 TW TW089118492A patent/TWI268279B/zh not_active IP Right Cessation
-
2001
- 2001-09-10 ZA ZA200107450A patent/ZA200107450B/xx unknown
- 2001-09-11 NO NO20014409A patent/NO327812B1/no not_active IP Right Cessation
-
2002
- 2002-05-02 HK HK02103316.9A patent/HK1041693B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200107450B (en) | Dimeric compounds and their use as inhibitors of neuraminidase. | |
HUP0105113A3 (en) | Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds | |
AP2003002857A0 (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors. | |
HK1044545A1 (zh) | 貝他分泌酶組合物及其方法 | |
ZA200108413B (en) | Use of glycosyceramide synthesis inhibitors in therapy. | |
HUP0200391A2 (en) | Use of pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth | |
HK1053124A1 (en) | Substituted quinazoline derivatives and their use as inhibitors | |
HUP0200347A2 (en) | N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use | |
HUP0202794A3 (en) | Oligonucleotides for inhibiting the expression of human eg5 | |
ZA988469B (en) | Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors | |
ZA200201275B (en) | Cyclic peptide derivatives as inhibitors of integrin alphavbeta6. | |
HK1048318B (zh) | 取代的3-苯基-5-烷氧基-1,3,4-噁二唑-2-酮及其作為脂酶抑制劑的用途 | |
HK1057900A1 (en) | 2-Aminothiazoline derivatives and their use as no-synthase inhibitors. | |
AU7402201A (en) | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | |
AU7608100A (en) | 1-cyclohexene-1-carboxylic acid and 1-cyclohexene-1-carboxylates as neuraminidase inhibitors | |
ZA200109120B (en) | Use of Arylalkanoylpyridazines. | |
AU7990000A (en) | Neuraminidase inhibitors | |
AU2039301A (en) | Neuraminidase inhibitors | |
SI1214302T1 (en) | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors | |
AU7831200A (en) | Neuraminidase inhibitors | |
SI1289514T1 (en) | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | |
ZA200105277B (en) | New amidinobenzylamine derivatives and their use as thrombin inhibitors. | |
AU2002340633A1 (en) | Dimeric pharmaceutical compounds and their use | |
HK1043362A1 (zh) | 稠環化合物及其作為藥物的應用 |